Shanghai Kehua Bio-Engineering (SHE:002022) received a device registration certificate from the drug administration of Shanghai for its creatine kinase isoenzyme assay kit (latex immunoturbidimetry), according to a Shenzhen Stock Exchange filing on Thursday.
The certificate is valid until Nov. 13, 2029, the Chinese in vitro diagnostics company said.